# Extension Study to Study PQ-110-001 (NCT03140969)

> **NCT03913130** · PHASE1,PHASE2 · TERMINATED · sponsor: **Laboratoires Thea** · enrollment: 9 (actual)

## Conditions studied

- Leber Congenital Amaurosis 10
- Blindness
- Leber Congenital Amaurosis
- Vision Disorders
- Sensation Disorders
- Neurologic Manifestations
- Eye Diseases
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Retinal Disease

## Interventions

- **DRUG:** QR-110

## Key facts

- **NCT ID:** NCT03913130
- **Lead sponsor:** Laboratoires Thea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-13
- **Primary completion:** 2022-10-03
- **Final completion:** 2022-10-03
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Terminated \[Study prematurely terminated due to sponsor decision for reasons unrelated to safety\]
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03913130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03913130, "Extension Study to Study PQ-110-001 (NCT03140969)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03913130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*